Skip to main content

Clara Carnicer Cáceres

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Clara Carnicer Cáceres

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies and therapies.

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Jorge Hernández Vara, Sara Lucas del Pozo, Eddie Pradas Gracia, Guillem Pintos Morell, Laura Castillo Ribelles, Clara Carnicer Cáceres, Carles Lorenzo Bosquet, David Moreno Martinez
Funding agency: Instituto de Salud Carlos III
Funding: 245932.5
Reference: PI20/00728
Duration: 01/01/2021 - 30/06/2025

Desarrollo de una nueva terapia de reemplazo enzimático basada en nanotecnología para la enfermedad de Parkinson: restablecimiento de la actividad glucocerebrosidasa lisosomal mediante nanoconjugación enzima-polímero de GBA (NANO-ERT).

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez
Funding agency: Fundación Banco Bilbao Vizcaya Argentaria
Funding: 124047.74
Reference: BBVA/INVESTIGACIO/MARTINEZ
Duration: 01/05/2020 - 30/07/2023

Validación funcional de variantes en el genoma mitocondrial y nuclear en pacientes con patologia mitocondrial

IP: Elena García Arumí
Collaborators: Mª Jesus Melia Grimal, Clara Carnicer Cáceres, Paula Fernández Álvarez
Funding agency: Instituto de Salud Carlos III
Funding: 102850
Reference: PI19/01772
Duration: 01/01/2020 - 31/12/2023

Enfermedades minoritarias causantes de degeneración de ganglios basales en pedriatría: implemementación combinada del análisis genómico y de biomarcadores.

IP: Belen Perez Dueñas
Collaborators: José Antonio Arranz Amo, Josefa Élida Vázquez Méndez, Alfons Macaya Ruíz, Anna Marcé Grau, Clara Carnicer Cáceres, Mireia Del Toro Riera, Ana Felipe Rucián, Amaia Lasa Aranzasti
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/01319
Duration: 01/01/2019 - 31/12/2022

Related news

The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.

The new system, made of cellulose and chitosan, enables sustained release of docetaxel and has demonstrated antitumor activity in preclinical models of ovarian cancer and glioblastoma.

The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.

Related professionals

Indira Correa García

Indira Correa García

Tècnic de recerca
Commercial and Academic Clinical Research
Read more
Alfons Macaya Ruíz

Alfons Macaya Ruíz

Head of group
Pediatric Neurology
Read more
Luis Fernando Zhu Ordoñez

Luis Fernando Zhu Ordoñez

Research technician
Diagnostic nanotools (DINA)
Read more
Karin Axel Patrick Angulo Diaz

Karin Axel Patrick Angulo Diaz

Research technician
Basic, Translational and Clinical Pharmacy Research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.